Building 1, Fourth Floor 4560 Jinke Road Pudong
86 21 6163 2588
Full-time employees: 2,036
|Dr. Ying Du Ph.D.||Founder, Chairperson & CEO||1.67M||N/A||1966|
|Mr. Joshua L. Smiley||Pres & COO||647.11k||N/A||1970|
|Dr. Rafael G. Amado M.D.||Pres and Head of Global Oncology R&D||477k||N/A||1964|
|Mr. Ki Chul Cho||Chief Financial Officer||748.24k||N/A||1978|
|Dr. Harald Reinhart M.D.||Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases||923.33k||68.6k||1952|
|Dr. Peter Huang Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Frazor Titus Edmondson III||Chief Legal Officer & Corp. Sec.||N/A||N/A||1966|
|Ms. Ann E. Beasley J.D.||Chief Compliance Officer||N/A||N/A||N/A|
|Dr. Ning Xu M.D.||Exec. VP & Head of Clinical Operations||N/A||N/A||1965|
|Dr. Jonathan J. Wang MBA, Ph.D.||Chief Bus. Officer||N/A||N/A||1982|
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.
Zai Lab Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.